In what shakes out to be the largest follow-on stock offering in biopharma history, Revolution Medicines Inc., an oncology company that was the subject of buyout rumors earlier this year, priced 10.56 million shares to raise $1.5 billion just two days after wowing investors with top-line phase III data of its RAS inhibitor daraxonrasib in patients with metastatic pancreatic ductal adenocarcinoma. Read More

A pricing standoff between Pfizer Inc. and the Australian government has left women with advanced breast cancer facing tens of thousands of dollars in out-of-pocket costs, underscoring a growing global trend in which access to life-extending drugs is increasingly being shaped by pricing negotiations rather than clinical merit. Read More

Alivecor Inc. has secured CE marking for its Kardia 12L electrocardiogram (ECG) system, which is powered by its KAI 12L AI technology and can detect life-threatening cardiac conditions. Kardia 12L is a portable, AI-guided, 12-lead ECG solution that delivers measurements and interpretations similar to standard 12-lead ECG solutions, right at the point of care. The company said the simplified design will enable faster acquisition of complete ECG data while leading to better patient outcomes. Read More

Med-tech M&A activity surged in March 2026, with deal value reaching $23.66 billion, the highest monthly total since June 2022’s $36.27 billion and a sharp increase from $17.53 billion in February and $1.69 billion in January. Read More

“Single drugs targeting single biological pathways are insufficient for complex diseases,” Remedy Cell Ltd. CEO Ayelet Dilion Mashiah told BioWorld. Remedy is taking a secretome-based approach to treat lung disorders, having moved its lead asset, RC-0315, into a first-in-human clinical trial for idiopathic pulmonary fibrosis (IPF) in January. Secretomes refer to the collection of bioactive molecules secreted by cells in the extracellular space, including proteins, enzymes, growth factors and extracellular vesicles such as exosomes. Read More

Eli Lilly and Co.’s buyout of Ventyx Biosciences Inc. for $1.2 billion at the start of the year brought to the forefront NLR family pyrin domain containing 3 (NLRP3) inhibitors, on which a handful of developers have been working – and research in the space continues to roll out, as with the paper published March 26 in Nature that delved into mechanisms that rev up the NLRP3 inflammasome. Read More

Despite key vacancies, ongoing staffing challenges and policy issues at the U.S. CDC, FDA and NIH, some of the regulatory churn that roiled those agencies in the first year of the second Trump administration is settling a bit, at least in terms of the number of executive orders (EOs) coming out of the Oval Office. Read More

New hires and promotions in the biopharma and med-tech industries, including: Adagene, Asgard, Harmony, Inspira, Kashiv, Kivu, Laigo, Panntherapi, Parabilis, Tempest, Valanx, Valo. Read More

Biopharma and med-tech companies raising money in public or private financings, including: Adcendo, Advanced Bionics, Alamar, Galera, Kailera, Obsidian, Senhwa, Spiral. Read More

Clinical updates for biopharma and med tech, including data readouts and publications: Actuate, Alkermes, Antiva, Biotronik, Clearmind, Kelun-Biotech, Kiora, Penumbra, Renovorx, Sirtex. Read More

Biopharma and med-tech happenings, including deals and partnerships, and other news in brief: 4D Path, Bioaffinity, Bostongene, Crossbridge, Daiichi, Eli Lilly, Immunogenesis, Harbinger, Kazia, Neurocrine, Novo Nordisk, Vasa, Vectus, Xortx. Read More

Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Grace, Holling, Ligand, Nxera, Praxis, Protaryx, Radical Catheter, Renaissance, Toby, Travere. Read More